The abstracts of the CTAD are available in PDF format, you can download them on
this link
The abstracts of the ICFSR are available in PDF format, you can download them on this link
this link
The abstracts of the ICFSR are available in PDF format, you can download them on this link
this link
Eisai and Biogen announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months… Continue Reading →
To facilitate disease-modifying clinical trials for Alzheimer’s Disease (AD), a blood-based amyloid-β (Aβ) biomarker, which can accurately detect an early pathological signature of AD at prodromal or preclinical stages, has been strongly desired, because it is simpler, less invasive and… Continue Reading →
Although the results were disappointing from two recent clinical trials of amyloid-targeting drugs in mild-to-moderate AD, the trials provided information that will be important for future studies, according to the EU-US CTAD Task Force, which met in November 2017 to… Continue Reading →
© 2025 Aging-news
